4C Medical Technologies

4C Medical Secures $175M Series D Preferred Stock Financing led by Boston Scientific

Before becoming CEO, Dr. Kumar served as vice president of R&D and operations for 3 years, and his team spearheaded development of AltaValve technology. Previously, Dr. Kumar was senior director of R&D and operations at Conventus Orthopaedics.

4C Medical develops minimally invasive technologies for structural heart disease. AltaValve is designed to expand the treatable severe MR population and eliminate known issues with current TMVR technologies.

The address is 6655 Wedgwood Rd., Suite 160, Maple Grove, MN 55311.

4C Medical develops minimally invasive technologies for structural heart disease. AltaValve is designed to broaden the treatable severe Mitral Regurgitation (MR) patient population and eliminate known issues in current Transcatheter Mitral Valve Replacement (TMVR) technologies.

Boston Scientific is leading a **$175 million funding round** for **4C Medical Technologies**, a medtech company developing a **transcatheter mitral valve replacement (TMVR) device**. The capital will advance a **pivotal trial** of the device in the **U.S. and Europe**, aiming to expand its clinical validation. The investment underscores growing industry focus on minimally invasive cardiac solutions.

Mar 2025MedTech DiveNews article

4C Medical raises $175 million in Series D preferred stock financing to expand its portfolio of minimally invasive therapies for structural heart conditions. The company develops medical devices targeting interventions like mitral valve repair and atrial septal defect closure. This funding supports continued innovation in cardiac care solutions.

Mar 2025PR NewswireNews article

4C Medical Technologies begins enrolling patients in a pivotal trial for its AltaValve System, a minimally invasive therapy for structural heart conditions. The trial marks a key step toward evaluating the device’s safety and efficacy in clinical settings. The company specializes in developing innovative solutions for heart disease treatment.

Oct 2024PR NewswireNews article

4C Medical receives two FDA Breakthrough Device Designations for its AltaValve System, accelerating patient access to advanced mitral valve therapies. The designations target minimally invasive treatments for structural heart conditions, aligning with the company’s focus on improving cardiac care outcomes.

May 2024PR NewswireNews article